Bio Bull
Long only, momentum, deep value

Evoke Pharma May Be One Of The Safest Biotech Bets Of 2014

Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

In the biotech industry, it can be difficult to identify a company with significant upside and limited risk. Evoke Pharma (NASDAQ:EVOK) is perhaps such a biotech stock. We believe it is deeply undervalued right now. The stock has received little attention in the media since its IPO. The result is that the stock is now being offered at a discount from the IPO price, and even the IPO price itself represents a market cap that fails to capture the value of this company. Evoke has...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details